Abstract Body

Background

Current WHO-recommended rifampicin (RIF) dosage results in inadequate concentrations in most children, but high-dose RIF (RIF-HD) may improve outcomes and shorten treatment duration. The impact of RIF-HD on dolutegravir (DTG) exposures among young children is unknown.

Methods

We designed a non-randomized, open-label, phase I/II pharmacokinetic (PK) and safety trial (NCT05069688) to evaluate steady-state DTG and RIF exposures among Nigerian children living with TB/HIV coinfection (4 weeks – 5 years) during standard-RIF (10-20 mg/kg) and RIF-HD consisting of weight-banded dosing that approximates exposures in adults receiving 35 mg/kg (based on Opti-Rif trial; Figure 1A). Children received weight-based DTG (twice daily) ART and standard TB therapy through week-20, after which additional RIF was given for two weeks to achieve steady-state RIF-HD. Intensive 24-hour PK sampling occurred at weeks 20 (standard-RIF) and 22 (RIF-HD). Primary PK targets include RIF peak serum concentration (Cmax) >8 mg/mL and DTG trough concentration (Ctrough) >0.32 mg/mL (EC90). Safety monitoring occurred at 7 visits during standard-RIF and weekly visits during RIF-HD.

Results

At interim analysis, 10 children (5 female) with median (range) age 3.5 (0.75-5) years and weight 10.8 (4.2-15.5) kg had complete PK visits at weeks 20 and 22. At week 20, only one of 10 (10%) children had RIF Cmax above the therapeutic target, while at week 22, 100% achieved Cmax >8 mg/mL while receiving RIF-HD (Figure 1B); geometric mean (GM) RIF Cmax was 3.5 mg/mL and 30.4 mg/mL, respectively. We observed no difference in DTG exposures during standard-RIF and RIF-HD, with GM DTG Ctrough of 1.7 and 2.1 mg/mL (all children had Ctrough >0.32 mg/mL), and AUC0-12 of 46.6 and 46.7 mg·h/ml, respectively. Serious adverse events were uncommon; importantly, no elevations of alanine aminotransferase or aspartate aminotransferase were observed during 2-weeks of RIF-HD (no grade 1-4). 

Conclusions

Most children did not achieve the minimum therapeutic Cmax target for rifampicin with standard weight-based dosing. High-dose RIF using weight-based dosing from the Opti-Rif trial achieved the target peak concentration in all children, without evidence of liver toxicity in this interim analysis. DTG exposures were unchanged during RIF-HD.  

Table or Figure